CCL2 and neoplasm: have shown that GBM recurrent tumors in mice had altered tumor-infiltrating myeloid cells polarization—shifting from a CD206+/CD86− to a CD206+/CD86+ profile between day 7 and 14 post-surgery—with significant increases of pro-tumorigenic cytokines (IL4, IL5, IL10, IL12, IL17, vascular endothelial growth factor VEGF, and monocyte chemoattractant protein 1 MCP1/CCL2) compared to primary tumors [69].